TG Therapeutics (TGTX) concentration risks

The company's disclosed concentration profile is defined by two high-share exposures — one product-side and one supply-chain — that together describe a business where both commercial success and manufacturing continuity rest on a narrow foundation. On the product side, the company's FDA-approved therapy BRIUMVI is the sole disclosed commercial asset — a high-share, mixed-character concentration. The mixed character reflects that BRIUMVI's approval is a structural achievement that supports commercial durability, while the dependency dimension arises from the reality that a single-product company has no revenue diversification if that product encounters safety, reimbursement, or competitive headwinds. On the supply side, the third parties relied upon for starting materials, intermediates, active pharmaceutical ingredient and drug substance are the sole source of supply — a high-share dependency covering the full manufacturing chain. Sole-source supply agreements in pharmaceutical manufacturing create a fragile production path: any quality failure, capacity constraint, regulatory action against the contract manufacturer, or contractual dispute would have no immediate alternative and could halt product supply to patients, with downstream effects on revenue and reputation. The interaction between these two exposures is significant. A single commercial product supplied through sole-source manufacturing partners means that disruptions can cascade: a manufacturing hold, for example, would affect the only revenue-generating asset. There is no disclosed diversification across either the product portfolio or the supply network to cushion such an event, making this concentration profile one where both commercial and operational monitoring warrant close attention.

For the engine’s reasoning on TGTX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.